Led · Equity · Feb 2025

ImpediMed specializes in medical technologies that use bioimpedance spectroscopy (BIS) to generate data for optimizing patient health. It produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for indications including lymphoedema, heart failure, and protein calorie malnutrition. The SOZO platform is sold in select markets globally. Led by Dr. Parmjot Bains, MD, CEO and Managing Director, the company intends to use the new proceeds to support continued execution of its commercial strategy. ImpediMed is based in Carlsbad, CA and was founded in Brisbane, Australia. The company recently raised $15M in growth funding.

Led · Debt Financing · Aug 2022

MedMinder offers a touchscreen-enabled, automatic pill dispenser that delivers medications from its integrated pharmacy in pre-organized daily trays for the entire month. The company combines its connected dispenser with convenient pharmacy services, personalized clinical care, and analytics aimed at improving adherence and reducing adverse outcomes for aging patients. Through relationships with health plans, home health agencies, provider organizations, long-term care facilities and advocacy groups, MedMinder supports medication management for thousands of seniors and polypharmacy patients and their caregivers. Founded in 2007, the organization employs over 180 team members and is described as an ultra-high-growth pharmacy care organization. MedMinder says it will use recent additional funding to increase capacity to meet growing demand and to offer its holistic pharmacy services nationally. The company plans to build out virtual care, clinical, and technological capabilities to further enable patients to age at home. MedMinder offers a touch screen–enabled automatic pill dispenser and integrated pharmacy service that delivers medications in pre-organized daily trays for an entire month and unlocks only at the prescribed time. The device monitors medication consumption and enables remote monitoring by caregivers and case managers on behalf of payors, as well as telemedicine connections with physicians. The company says it empowers thousands of patients to live more independently while improving adherence. MedMinder was founded in 2007 and is described in the announcement as an ultra-high-growth digital healthcare company. It currently employs over 100 team members across Massachusetts and New York. Management is focused on expanding its connected care and telehealth capabilities and scaling operations. MedMinder is a Needham, MA-based provider of a dispensing system designed to simplify medication management and improve adherence. The company offers pill dispensers paired with alert systems to help patients take medications on schedule. Its service model emphasizes surrounding the patient with a support network of family, friends and professional caregivers. Leadership cited in the article includes Eran Shavelsky (Founder and CEO), Brian Bouvier (Chief Pharmacy Officer), Andrew S. Dibner, Ph.D., and Woodie Flowers, Ph.D. No operating metrics or revenue figures were disclosed in the article. In October 2016 the company received an external investment. MedMinder Systems develops a wireless pill dispenser paired with a complementary medication-management service. The device prompts users to take or refill medications using optional pre-programmed visual and/or auditory alerts. Caregivers and family members can receive real-time email or text notifications about dosage activity, access periodic reports, or log in to review user data. The system is positioned to help users maintain independence and improve medication adherence while keeping families informed. The company is based in Needham, MA and its product emphasizes remote monitoring and caregiver visibility. According to SEC filings, MedMinder recently completed an equity financing round, indicating recent outside investor interest.

Led · Equity · Dec 2013

SynCardia makes the Total Artificial Heart, a temporary device that replaces both failing ventricles and the four heart valves. Following surgery and recovery, medically stable patients use the portable Freedom driver to power the SynCardia Heart; the Freedom driver is CE‑approved in Europe, completed U.S. clinical trials under an FDA IDE study, and the company is awaiting FDA market approval. The FDA granted Humanitarian Use Device (HUD) designation for the 70cc Total Artificial Heart for destination therapy, and SynCardia is pursuing a Humanitarian Device Exemption (HDE) that, if approved, would allow up to 4,000 transplant‑ineligible patients annually to receive the device. The company is developing a smaller 50cc version of its temporary Total Artificial Heart and raised $14 million to support that effort. Operationally, SynCardia reports tripled sales, has hired 40 people, and spent more than $2.5 million on Tucson facility expansion and new equipment over the last three years. As of Dec. 16, the company recorded 155 SynCardia Total Artificial Heart implants in 2013, nearly double its 2011 record of 81. Recent financing activity includes contributions from SWK Holdings and Athyrium Capital Management and the company raised $19 million earlier in the year.